ScienceDaily (Oct. 1, 2012) — Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City have shown that a new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer (TNBC) cells. Study findings presented October 1 at the 2012 Annual Clinical Congress of the American College of Surgeons could lead to a more targeted therapy against this deadly form of breast cancer.
Share This:
See Also:
According to the medical literature, TNBC is a form of breast cancer that is responsible for 10 to 20 percent of all breast cancer cases. TNBC is most likely to occur in younger women (
Share This:
See Also:
According to the medical literature, TNBC is a form of breast cancer that is responsible for 10 to 20 percent of all breast cancer cases. TNBC is most likely to occur in younger women (